Aldoxorubicin is primarily used in the treatment of cancer, particularly soft tissue sarcoma and glioblastoma. It functions as a prodrug of doxorubicin, designed to improve the therapeutic index by reducing cardiotoxicity. The drug binds to albumin in the bloodstream, allowing for targeted delivery to tumor tissues. This mechanism enhances its accumulation in cancer cells while minimizing damage to healthy tissues. Aldoxorubicin is also being investigated for its potential in treating other solid tumors and metastatic cancers, offering a promising approach for patients who may not respond well to traditional chemotherapy. Its ability to deliver a higher dose of the active drug with fewer side effects makes it a valuable option in oncology.